SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US
‘Best-In-Class Clinical Performance’: 100% Sensitivity And 100% Specificity
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
